GV.PA Genomic Vision (EURONEXT) pre-market €0.002 14 Mar 2026: 38.49M shares most active

GV.PA stock is the pre-market standout on EURONEXT on 14 Mar 2026, trading at €0.0018 with 38.49M shares in early activity. The tiny market cap of €693,191 and extreme volume spike (relative volume 2.71x) flag short-term liquidity and speculative trading rather than fundamental repositioning. Investors should weigh the unusual turnover against negative earnings (EPS -0.11) and stretched valuation metrics before positioning for a bounce.

GV.PA stock pre-market activity and price action

Genomic Vision SA (GV.PA) opens pre-market on EURONEXT at €0.0018 with a day range €0.0015–€0.0020 and intraday change +5.88%. Volume of 38.49M shares dwarfs average daily volume 14.22M, making GV.PA one of the most active names in Europe this session. Short-term technicals show price below the 50-day average (€0.00484) and 200-day average (€0.013997), emphasising momentum is supply-driven not trend-confirming.

Financial snapshot and key ratios for GV.PA stock

The company reports EPS -0.11 and a negative P/E (reported -0.016), reflecting consistent losses. Price-to-sales is 0.47, enterprise value to sales 1.60, and current ratio near 0.91, signalling tight liquidity. Cash per share is 0.00557 while shares outstanding are 385,105,984, producing a micro market cap €693,191. These figures point to high leverage relative to equity measures and an elevated risk profile.

Business model, partnerships and sector context

Genomic Vision develops single DNA detection tools including FiberVision and FiberComb, and holds alliances with Quest Diagnostics and research agreements with Institut Pasteur. The company sits in Healthcare — Medical Diagnostics; the healthcare sector average P/E is near 29.24, showing GV.PA’s valuation profile is far detached from peers. Commercial partnerships support long-term relevance but have not yet translated into profitable scale.

Meyka AI rates GV.PA with a score out of 100

Meyka AI rates GV.PA with a score out of 100: 62.60 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The score reflects very high trading activity but weak fundamentals and liquidity risks. These grades are informational only and not financial advice.

Technical and liquidity analysis for GV.PA stock

Price sits below the important moving averages (50-day €0.00484, 200-day €0.013997). RelVolume is 2.71, signalling outsized order flow. Year high €0.094 vs year low €0.0014 shows extreme drawdown. Market participants should note average payables and inventory cycles are stretched, while free cash flow per share is negative, keeping technical rallies vulnerable to quick reversals.

Risks, opportunities and realistic price targets

Key risks: repeated operating losses, low liquidity despite volume spikes, and potential further dilution. Opportunities include product adoption and partnerships converting to commercial revenue. Realistic price targets: conservative €0.0015, base €0.0030, optimistic €0.0100. No formal analyst consensus exists; price targets are scenario-based and hinge on revenue traction.

Final Thoughts

GV.PA stock is the session’s most active micro-cap on EURONEXT with €0.0018 current price and 38.49M pre-market volume. The trading picture mixes speculative liquidity and headline activity with weak fundamentals: EPS -0.11, price-to-sales 0.47, and market cap €693,191. Meyka AI’s forecast model projects a 12-month reference target of €0.0060, implying an upside of +233.33% versus the current price €0.0018; forecasts are model-based projections and not guarantees. For traders, the stock offers high short-term volatility and potential quick gains, but for investors it remains a high-risk hold until cash flow turns positive or commercial revenue accelerates. We recommend monitoring volume, partnership updates, and any dilution events before increasing exposure. For real-time tick and order-book updates, see the Genomic Vision page on Meyka AI and recent market headlines source source.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.